Article No
AG-27B-6003PF-C100
anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His)
anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His)
Antibodies Primary
Specifications
| Additional Information | This cross-domain human antibody is a selective ADAM17 (TACE) antagonist and provides a unique alternative to small molecule metalloprotease inhibition. ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound ADAM17-specific non-catalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the ADAM17 catalytic domain. This monovalent Fab Antibody has been shown by C.J. Tape, et al.; PNAS 108, 5578 (2011) to be as active as the divalent antibody (Prod. No. AG-27B-6000). |
| Application | Block, FA |
| Article No | AG-27B-6003PF-C100 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT |
| Clone | D1(A12) |
| Clone Type | monoclonal |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Description | anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His) |
| Supplier | Adipogen Life Sciences |
| Endotoxin | <0.001EU/µg |
| Entrez Gene ID | 6868 |
| Additional Information | This cross-domain human antibody is a selective ADAM17 (TACE) antagonist and provides a unique alternative to small molecule metalloprotease inhibition. ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound ADAM17-specific non-catalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the ADAM17 catalytic domain. This monovalent Fab Antibody has been shown by C.J. Tape, et al.; PNAS 108, 5578 (2011) to be as active as the divalent antibody (Prod. No. AG-27B-6000). |
| Format | Liquid |
| Gene Symbol | ADAM17 |
| Immunogen | Recombinant human ADAM17 (TACE) ectodomain tagged to biotin. |
| Notes | ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer.|Recombinant Antibody. Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain. Species cross-reactivity: Human. Clone: D1(A12). Isotype: Human Fab fragment, kappa, His-tagged. Applications: FUNC, FUNC (Blocking). Host: E. coli. Liquid. In PBS. ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer. |
| Alias Names | TNF-alpha-converting Enzyme; Disintegrin and Metalloproteinase Domain-containing Protein 17; CD156b |
| Product Type | Antibodies Primary |
| Protocol | This cross-domain human antibody is a selective ADAM17 (TACE) antagonist and provides a unique alternative to small molecule metalloprotease inhibition. ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound ADAM17-specific non-catalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the ADAM17 catalytic domain. This monovalent Fab Antibody has been shown by C.J. Tape, et al.; PNAS 108, 5578 (2011) to be as active as the divalent antibody (Prod. No. AG-27B-6000). |
| Purity | >95% |
| Research area | Inflammation |
| Shipping Information | BLUE ICE |
| Size | 100 ug |
| Source / Host | human |
| Species Reactivity | human |
| Stability | Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C. |
| Storage | -20°C, 4°C |
| Substrate / Buffer | Liquid. In PBS. |
| Technical Specifications | Recombinant Antibody. Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain. Species cross-reactivity: Human. Clone: D1(A12). Isotype: Human Fab fragment, kappa, His-tagged. Applications: FUNC, FUNC (Blocking). Host: E. coli. Liquid. In PBS. ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer. |
| UniProt Number | P78536 |
| Product Page Updated | 2024-02-01T08:25:01.492Z |
